clinical trial · NCT05274750
Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps
GlaxoSmithKline·phase3·completed·n = 276
Nasal PolypsDepemokimab (GSK3511294)Placebo
brief summary
This study will evaluate the efficacy and safety of depemokimab (GSK3511294) in participants with Chronic rhinosinusitis with nasal polyps (CRSwNP).
started
Apr 22, 2022
primary completion
Jul 30, 2024
completion
Aug 27, 2024
last updated
Dec 3, 2025
official title
A Randomised, Double-blind, Parallel Group Phase III Study to Assess the Efficacy and Safety of 100 mg SC Depemokimab in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) - ANCHOR-1 (depemokimAb iN CHrOnic Rhinosinusitis)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol